follow
discoveri
earli
niclosamid
figur
initi
use
molluscicid
kill
around
decad
later
found
effect
human
tapeworm
use
human
treat
tapeworm
infect
start
follow
approv
us
food
drug
administr
fda
sinc
world
health
organ
essenti
list
medicin
structur
niclosamid
belong
larg
group
lipophil
weakli
acid
molecul
call
salicylanilid
figur
despit
wide
use
anthelmint
drug
mechan
action
niclosamid
yet
complet
understood
earli
studi
link
niclosamid
activ
uncoupl
oxid
howev
last
decad
niclosamid
shown
act
target
mtor
signal
pathway
review
chen
et
inevit
link
niclosamid
therapeut
potenti
mani
diseas
involv
import
signal
cascad
increas
interest
niclosamid
last
decad
reflect
signific
increas
number
public
regard
studi
drug
figur
herein
briefli
discuss
numer
diseas
niclosamid
shown
promis
treat
mutat
impair
catalyt
activ
mitochondri
serinethreonin
protein
kinas
kinas
found
caus
earli
onset
neuron
apoptosi
becam
appar
small
molecul
activ
would
neuroprotect
effect
thu
potenti
treat
equip
fact
activ
mitochondri
depolar
barini
et
investig
whether
known
caus
mitochondri
depolar
could
activ
result
show
niclosamid
potent
activ
cell
studi
show
niclosamid
direct
activ
activ
observ
recombin
incub
vitro
howev
shown
niclosamid
caus
mitochondri
depolar
phenomenon
found
revers
follow
remov
niclosamid
cell
impress
niclosamid
also
shown
activ
cultur
neuron
togeth
studi
highlight
neuroprotect
promis
niclosamid
may
hold
vivo
studi
pd
model
need
establish
abil
niclosamid
treat
diseas
niclosamid
ethanolamin
salt
form
niclosamid
exhibit
improv
aqueou
solubl
shown
improv
symptom
inde
niclosamid
treatment
mice
fed
diet
led
improv
metabol
increas
lipid
oxid
high
energi
expenditur
addit
dbdb
mice
wherein
diabet
induc
result
mutat
caus
defici
leptin
receptor
activ
niclosamid
ethanolamin
shown
effect
improv
glycem
control
treat
hyperglycemia
slow
progress
diseas
subsequ
studi
niclosamid
piperazin
anoth
salt
form
niclosamid
also
found
similar
efficaci
treat
suggest
niclosamid
antidiabet
therapeut
potenti
due
inhibit
glucagon
signal
pka
niclosamid
also
shown
antimicrobi
activ
variou
bacteri
infect
staphylococcu
aureu
mrsa
tuberculosi
tb
drug
repurpos
studi
use
librari
drug
niclosamid
found
specif
inhibit
growth
bacteria
display
strong
vivo
vitro
activ
mrsa
find
show
niclosamid
effect
vancomycin
current
drug
choic
treat
subsequ
niclosamid
investig
potenti
antimicrobi
surfac
coat
highli
versatil
antimicrobi
coat
develop
shown
clear
exist
infect
prevent
biofilm
format
low
niclosamid
also
shown
signific
antituberculosi
tb
activ
interestingli
niclosamid
exert
pharmacolog
activ
tubercl
bacilli
tuberculosi
howev
potenti
toxic
mammalian
cell
note
niclosamid
use
mic
henc
topic
use
niclosamid
tuberculosi
may
hold
better
therapeut
promis
furthermor
niclosamid
identifi
abl
significantli
protect
cell
anthrax
lethal
toxin
well
lethal
factor
pseudomona
exotoxin
fusion
protein
diphtheria
toxin
low
micromolar
activ
link
obstruct
process
anthrax
toxin
intern
directli
link
endosom
niclosamid
suggest
potenti
use
antivir
target
host
pathway
use
virus
infect
unlik
current
antivir
strategi
direct
specif
viral
broad
antivir
activ
niclosamid
link
abil
neutral
endosom
ph
therebi
disrupt
membran
fusion
requir
viral
entri
date
sever
studi
indic
potenti
use
niclosamid
treat
coronavirus
chikungunya
viru
ebola
niclosamid
discov
abl
inhibit
replic
low
micromolar
concentr
viral
antigen
synthesi
total
abolish
niclosamid
concentr
low
exact
mode
action
clear
niclosamid
found
interfer
virion
attach
entri
cell
still
activ
even
ad
three
hour
viral
infect
cell
silico
studi
suggest
potenti
bind
niclosamid
main
howev
modest
activ
niclosamid
proteinas
report
moreov
niclosamid
exhibit
antivir
activ
chikungunya
viru
chikv
use
chikv
insect
cell
fusion
screen
assay
abl
inhibit
viru
entri
transmiss
chikv
light
recent
outbreak
zika
ebola
infect
focu
drug
repurpos
screen
drug
rapid
identif
potenti
therapeut
agent
meet
urgent
medic
need
treat
infect
use
approach
niclosamid
identifi
inhibitor
zika
valid
assay
confirm
abil
niclosamid
significantli
decreas
zika
rna
level
suppress
product
infecti
zika
particl
subsequ
niclosamid
emerg
posit
hit
anoth
drug
repurpos
screen
aim
identifi
clinic
use
agent
may
activ
ebola
viru
diseas
receiv
far
attent
repurpos
niclosamid
cancer
date
niclosamid
shown
exhibit
anticanc
activ
adrenocort
observ
anticanc
activ
link
niclosamid
abil
damag
tumor
cell
mitochondria
induc
apoptosi
inhibit
tumor
cell
prolifer
inhibit
variou
aberr
tumor
signal
pathway
includ
nuclear
notch
pathway
review
detail
moskaleva
et
addit
anticanc
activ
niclosamid
also
shown
inhibit
cancer
stem
consid
attract
promis
anticanc
therapeut
target
accumul
evid
establish
crucial
role
cancer
initi
progress
establish
recurr
drug
beyond
use
singl
agent
niclosamid
studi
combin
convent
chemotherapeut
agent
instanc
combin
niclosamid
cisplatin
led
inhibit
breast
exhibit
synergist
effect
lung
cancer
enhanc
sensit
chronic
myeloid
leukemia
cell
cervic
cancer
cell
also
achiev
drug
use
combin
niclosamid
synergist
effect
erlotinib
colon
head
neck
lung
cancer
also
describ
combin
niclosamid
bicalutamid
led
overcom
prostat
combin
abirateron
found
effect
treat
advanc
prostat
furthermor
use
niclosamid
conjunct
radiotherapi
result
signific
radiosensit
effect
breast
cancer
overcam
lung
along
interest
repurpos
niclosamid
variou
diseas
must
note
niclosamid
abil
influenc
mani
signal
pathway
may
work
disadvantag
would
lead
divers
side
effect
also
favor
safeti
profil
niclosamid
treat
human
tapeworm
infect
could
due
fact
site
action
case
gut
henc
drug
absorb
modul
variou
signal
cascad
caus
side
effect
newli
discov
diseas
niclosamid
may
therapeut
effect
system
deliveri
mayb
requir
henc
safeti
profil
niclosamid
case
still
larg
unknown
current
futur
vivo
studi
niclosamid
provid
clearer
pictur
efficaci
toxic
determin
success
repurpos
initi
niclosamid
shown
great
promis
treat
mani
diseas
uncoupl
oxid
phosphoryl
manipul
variou
cascad
safeti
concern
may
aris
follow
system
exposur
insight
safeti
issu
attain
near
futur
variou
ongo
clinic
investig
niclosamid
statement
brief
highlight
niclosamid
pharmacolog
activ
imposs
includ
studi
publish
niclosamid
area
studi
discuss
work
repres
sampl
myriad
niclosamid
therapeut
activ
author
declar
conflict
interest
